Press Room


    Press Release - August 01, 2006

    Pheromone Builds Scientific Advisory Board: Sertoli Cell Expert Dr. Jannette Dufour to Help Develop Diabetes Product

    Kelowna, B.C. -- Pheromone Sciences Corp. ("Pheromone") is pleased to announce that Dr. Jannette Dufour, PhD has joined its Scientific Advisory Board ("SAB") to assist the company with its diabetes product development.

    "Because Sertoli cells are a key component of our project, Dr. Dufour's extensive research into these cells significantly enhances our team," stated Dr. David White, Chair of Pheromone's SAB. "Her experience working for the University of Alberta's Clinical Islet Transplant Program [originators of the prominent 'Edmonton Protocol'] will be particularly valuable."

    Currently Assistant Professor in the Department of Cell Biology and Biochemistry at Texas Tech University Health Sciences Center in Lubbock Texas, Dr. Dufour's research was instrumental in developing the technology leading to some of the Sertoli cell patents now licensed exclusively to Pheromone. The Company owns the exclusive rights to over 20 patents related to the therapeutic use of Sertoli cells.

    About Dr. Dufour In 1999 Dr. Dufour received a PhD in Genetics and Cell Biology from Washington State University, where she first began research on Sertoli cells as a graduate student. She then went on to receive further training as a postdoctoral fellow with Drs. Rajotte and Korbutt with the Islet Transplantation Program at the University of Alberta. While there she received five postdoctoral fellowships to study the use of Sertoli cells as a way to immunoprotect transplanted islets. Dr. Dufour is now an Assistant Professor at Texas Tech University Health Sciences Center where she continues to investigate the immunoprotective properties of Sertoli cells with the goal of developing ways to improve the survival of transplanted islets.

    Pheromone Sciences Corp. is a biotechnology research and development company focused on commercializing medical technologies.


    "Dev Randhawa"

    Dev Randhawa, CEO

    For further information contact: Mr. Phil Morehouse Pheromone Sciences Corp. TEL: (250) 868-8177 FAX: (250) 868-8493


    Press Releases from:

    2018 2017 2016 2015 2014 2013 2012

    2011 2010 2009 2008 2007 2006 2005

    2004 2003 2002 2001 2000 1999

    Featured News

    2014, January 22

    Sernova’s Disruptive Regenerative Medicine Technologies Set to Improve the Treatment of Chronic Diseases While Reducing Healthcare Costs


    2012, July 11

    Sernova Corp. developing a tiered approach to the treatment of diabetes

    Publisher: Canadian Investor Magazine
    Author: Rochelle Emnance


    2012, July 30

    Feds back local diabetes discovery

    Publisher: London Free Press
    Author: Norman De Bono

    2012, July 30

    Federal program pumps $3 million into new, London business

    Publisher: The London Free Press

    Author: Norman De Bono

    2010 July 10

    Canada's economic action plan supports business innovators

    Publisher: Federal Economic Development Agency for Southern Ontario


    2007, February 20

    "Transplanted cells may protect against diabetes without forced drug use: An interview with Dr. David White"

    Author: Julie Ickes and James Finch

    2006, October 04

    "Sertoli Cells: Mother nature's anti-rejection drug"

    Author: James Finch

    2006, August 24

    "Mass marketing diabetes reversal; novel xeno-transplants may offer new hope for type 1 diabetics"

    Author: James Finch

    Presentation and Video

    May 03, 2018

    Corporate Presentation

    April 2018

    March 29, 2018

    2018 Financial Report - 1st Quarter

    March 29, 2018

    2018 Management Discussion & Analysis (MD&A) - 1st Quarter

    December 11, 2017

    Clearance by FDA of Sernova's US IND

    Conference call audio recording

    September 11, 2017

    Sernova Fact Sheet

    Subscribe to Sernova News